♥ HF Guideline NavigatorESC 2026

6 › 6.1 › 6.1.4

6.1.4 Foundational therapy for HFrEF (RAS inhibitors, beta-blockers)

Pages 33–34 · open in PDF

Recommendations in this section

  • Class ILevel AAn SGLT2-I (dapagliflozin or empagliflozin) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death.
  • Class ILevel AAn MRA (sMRA for HFrEF and sMRA/nsMRA for HFpEF) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death.
  • Class ILevel ADynamic individualized dosing of loop diuretics according to volume status is recommended in patients with HF and signs and/ or symptoms of congestion to alleviate HF symptoms, improve exercise capacity, and reduce the risk of HFH.
  • Class ILevel CUptitration of FMT at least every 1–2 weeks in patients with HF, guided by symptoms, vital signs, and laboratory findings, to achieve optimal target doses shown to be efficacious in RCTs is recommended to reduce the risk of HFH or death.
  • Class ILevel CContinuation of FMT at the highest tolerated doses is recommended in all patients with HF, including those who become asymptomatic or with LVEF improvement, in order to reduce the risk of HFH and death.
  • Class ILevel AA beta-blocker is recommended in stable patients with symptomatic HFrEF to reduce the risk of HFH and death.
  • Class ILevel AAn ACE-I or ARNI is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and death.
  • Class ILevel B1Switching from an ACE-I or ARB to an ARNI is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and death.
  • Class ILevel AAn ARB is recommended in patients with symptomatic HFrEF to reduce the risk of HFH and CV death if they are unable to tolerate an ACE-I or ARNI.
  • Class IIaLevel B1A cardiac glycoside (digoxin or digitoxin) should be considered in patients with symptomatic HFrEF with LVEF ≤40%, despite optimal FMT, to reduce the risk of HFH.
  • Class IIaLevel B1Ivabradine should be considered for patients with symptomatic HFrEF, LVEF ≤ 35%, in sinus rhythm, resting heart rate >70 b.p.m., on the highest tolerated ACE-I/ARNI, MRA, SGLT2-I, and beta-blockers to reduce the risk of HFH or CV death.
  • Class IIaLevel CIvabradine should be considered in patients with symptomatic HFrEF, LVEF ≤ 35%, in sinus rhythm, who are unable to tolerate a beta-blocker, on the highest tolerated ACE-I/ARNI and MRA to reduce the risk of HFH or CV death.
  • Class IIaLevel B2Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with symptomatic HFrEF with LVEF ≤ 40% on top of optimal FMT to reduce the risk of HFH and death.
  • Class IIbLevel CHydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF with LVEF ≤ 40% who cannot tolerate ARNI, ACE-I, or ARB to reduce the risk of HFH and death.
  • Class IIbLevel B1Vericiguat may be considered in patients with symptomatic HFrEF and LVEF <45% despite treatment with optimal FMT to reduce the risk of HFH and CV death.
  • Class IIbLevel CGradual discontinuation of FMT under frequent clinical, laboratory, and imaging surveillance may be considered in highly selected patients who are asymptomatic with complete normalization of LV function and volume as well as natriuretic peptide levels after specific treatment of reversible causes of HF, in order to accommodate patient preference.
  • Class IIbLevel CACE-I/ARB/ARNI may be considered in patients with symptomatic HFpEF to reduce the risk of HFH.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 33 · PDF

6.1.4. Foundational medical therapy for heart failure with reduced ejection fraction Modulation of the renin–angiotensin–aldosterone system, sympathetic nervous systems, and sodium–glucose co-transporter (SGLT2) inhibition has been shown to improve survival, reduce the risk of HFH, and reduce symptoms in patients with HFrEF. Treatment with optimal FMT, including ACE-Is/ARNIs/ARBs, beta-blockers, MRAs, and SGLT2-Is, is recommended as the foundation of treatment for all patients with HFrEF. There is no evidence favouring any particular sequencing during initiation and uptitration. Therefore, the consensus is that FMT can be commenced together with individual variations based on clinical assessment as soon as the diagnosis of HFrEF is established. Drugs should be uptitrated and continued at the doses used in the RCTs (or to the highest tolerated doses). Misinterpretation of changes in kidney function is a leading cause of insufficient dosing or inappropriate discontinuation of FMT and should be avoided (Section 6.1.6).273 Additional medical therapy may be used in selected patients with HFrEF (see Section 6.1.5). No large prospective RCT has been performed exclusively in patients with LVEF 41%–49%. Patients with LVEF 41%–49% appear to respond to FMT, similar to patients with LVEF <40%.36,38–41 Many patients with LVEF 41%–49% may already be on ACE-Is or ARBs and beta-blockers for other CV indications such as CAD, hypertension, or post-MI LV systolic dysfunction. Sodium–glucose co-transporter 2 inhibitors and MRAs are recommended for all ranges of LVEF, as covered in Section 6.1.2. The recommended doses of FMT and AMT are provided in Table 11. Practical guidance in the use and uptitration of FMT are provided in Supplementary material online, Tables S4–S9.

6.1.4.1. Angiotensin-converting enzyme inhibitors and angiotensin receptor–neprilysin inhibitor Angiotensin-converting enzyme inhibitors were the first class of drugs shown to reduce mortality and morbidity and to improve symptoms in patients with HFrEF.137,138,274–277 They are

recommended in all patients with HFrEF unless contraindicated or not tolerated and should be uptitrated to the highest recommended doses. If these doses are not tolerated, intermediate doses should be tried. In the higher end of LVEF, evidence is limited. The PEP-CHF trial (perindopril) was conducted in patients with an LVEF >40%, but it did not report outcomes according to LVEF.39 The PEACE trial reported a subgroup analysis showing a reduction in mortality with trandolapril in patients with LVEF from 40% to 50%.38 An ARNI is composed of an ARB and an inhibitor of neprilysin, an enzyme that degrades natriuretic peptides, bradykinin, adrenomedullin, and other vasoactive peptides. In the PARADIGM-HF trial, the ARNI, sacubitril–valsartan, was compared with enalapril in symptomatic patients with HFrEF who already tolerated an adequate dose of either an ACE-I or an ARB.278 ARNI significantly reduced the composite endpoint of CV death or HFH by 20% as compared with enalapril.278 Additional benefits included improvement in QoL, reduction in decline of eGFR, a reduction in loop diuretic dose, and lower risk of hyperkalaemia.279,280 If patients continue to have chronic symptomatic HFrEF and they tolerate an ACE-I or an ARB, it is recommended that they be switched to an ARNI to reduce morbidity and mortality. Pre- and post-discharge initiation of ARNIs in HFrEF patients have shown similar efficacy and safety, and larger NT-proBNP reductions compared with ACE-I treatment ̈ patients.281–283 As such, the use of an in ACE-I/ARB naive ARNI may be efficacious as de novo treatment in patients with symptomatic chronic HFrEF to simplify management and maintain eGFR and QoL. Use of an ARNI is more frequently associated with symptomatic hypotension, and a washout period of at least 36 h after ACE-I therapy is required to minimize the risk of angio-oedema. Treatment with ACE-Is or ARNIs is indicated, but should be given with caution, to patients with low blood pressures (systolic blood pressure <100 mmHg), kidney insufficiency (eGFR <30 mL/min/ 1.73 m2), or elevated serum potassium (>5.2 mEq/L). Abrupt withdrawal of ACE-Is or ARNIs can lead to clinical deterioration and should be avoided, and in those patients for whom treatment with an ARNIs is not possible, continued use of an ACE-I remains strongly advised.

6.1.4.2. Angiotensin II type 1 receptor blockers Angiotensin II receptor blockers are recommended for HFrEF patients who cannot tolerate ACE-Is or ARNIs due to side effects. Unlike ACE-Is, ARBs do not inhibit kininases and are associated with a much lower incidence of cough and angio-oedema. In the CHARM-Alternative study, candesartan reduced CV death and HFH in patients who were not receiving an ACE-I due to previous intolerance.284 In the HEAAL study, high-dose losartan reduced HFH compared with low-dose losartan in ACE-I intolerant patients.285 Valsartan, in addition to usual therapy, including ACE-Is, reduced HFH in the Val-HeFT trial.286 However, no ARB has reduced all-cause mortality in any trial, and combination with an ACE-I increases adverse effects. Also, in patients with higher LVEF, evidence is limited. The CHARM-Preserved trial did not show a reduction in its primary endpoint of CV death or HFH, but a retrospective analysis showed that candesartan reduced the number of patients hospitalized for HF among those with LVEF 40%–49%.40,41

and because of HF itself. Hyperkalaemia may increase the risk for arrhythmias and death.268 Hyperkalaemia, and the fear of inducing it, often results in under-utilization, dose reductions, or discontinuation of ACE-Is/ARNIs/ARBs and MRAs compromising their cardio-kidney benefit in HF. The gastrointestinal potassium binders patiromer and sodium zirconium cyclosilicate remove potassium by exchanging cations, leading to increased faecal excretion. Both agents have shown favourable results to treat and/or prevent hyperkalaemia in patients receiving ACE-Is/ARNIs/ ARBs and MRAs, therefore facilitating the continuation or uptitration of ACE-Is/ARNIs/ARBs and MRAs.269–272 Whether potassium binders improve clinical outcomes is still unclear. In the REALIZE-K trial, there was a signal towards more HF deterioration with sodium zirconium cyclosilicate as compared with placebo, although the trial was not powered to detect clinical outcomes.272 Potential adverse effects for the potassium binders include gastrointestinal symptoms (nausea, constipation, diarrhoea), hypomagnesaemia (for patiromer), and oedema (for sodium zirconium cyclosilicate). No specific recommendations for the use of potassium binders are included in the guideline at current time, due to insufficient evidence for clinical benefit.

Page 34 · PDF

6.1.5. Additional medical therapy for heart failure with reduced ejection fraction 6.1.5.1. If-channel inhibitor (ivabradine) Ivabradine should be considered in patients with symptomatic HFrEF who at rest are in sinus rhythm with heart rate ≥70 b.p.m., LVEF ≤35%, and recent HFH, despite stable FMT including optimized beta-blocker therapy.294 Ivabradine slows heart rate by inhibition of the If current. In the SHIFT trial, the primary composite endpoint of CV death or HFH was reduced, mainly driven by a reduction in HFH.294 Importantly, only 25% of patients studied in the trial were on optimal doses of betablockers.294 As beta-blockers have well-proven morbidity and mortality benefits, they should be initiated and uptitrated to target doses first, before assessing the resting heart rate for consideration of adding ivabradine.

6.1.5.2. Vericiguat The oral soluble guanylate cyclase stimulator vericiguat may be considered in patients with symptomatic HFrEF and LVEF <45% despite optimal FMT. The VICTORIA study assessed the efficacy and safety of vericiguat in patients with LVEF <45% and with recent episodes of WHF, who were already on the highest tolerated FMT. The incidence of the primary endpoint of CV death or HFH was lower among those who received vericiguat than among those who received placebo.295 There was no reduction in either all-cause or CV death. The much higher event rate in VICTORIA compared with other RCTs in patients with HFrEF was associated with a shorter median follow-up to acquire the total number of events needed, which may explain why HFH were reduced, but CV

mortality was not significantly reduced.296 There was also heterogeneity in a subgroup analysis, with less benefit in patients with the highest NT-proBNP levels. The VICTOR study evaluated vericiguat in ambulatory patients with HFrEF (LVEF ≤40%) who did not have a recent WHF event and who were on contemporary FMT. VICTOR was neutral for the primary composite endpoint of time to CV death or HFH (HR 0.93; 95% CI 0.83–1.04; P = .22).297 Over a median follow-up of ∼18.5 months, CV death was numerically lower with vericiguat (9.6% vs 11.3%; HR 0.83; 95% CI 0.71–0.97), whereas HFH was similar between groups (11.4% vs 11.9%; HR 0.95; 95% CI 0.82– 1.10). The trial therefore did not confirm a primary composite benefit in a stable, well-treated ambulatory HFrEF population, although pooled analyses combining VICTOR and VICTORIA suggest benefit across the broader HFrEF spectrum. Also, there was a reduction in all-cause mortality, a secondary endpoint in the trials.298,299

6.1.5.3. Hydralazine and isosorbide dinitrate There is no clear evidence to recommend the use of hydralazine and isosorbide dinitrate in all patients with HFrEF. In a small RCT conducted in self-identified black patients the addition of the combination of hydralazine and isosorbide dinitrate to conventional therapy at that time (an ACE-I, a beta-blocker, and an MRA) reduced mortality and HFH, and improved QoL in patients with symptomatic HFrEF.300 It is unclear if a benefit of hydralazine and isosorbide dinitrate exists for non-black patients with HFrEF. Additionally, a combination of hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who cannot tolerate any of an ACE-I, an ARNI, or an ARB (or if they are contraindicated) to potentially reduce HFH and mortality. This recommendation is based on the results of the Veterans Administration Cooperative Study, which included only male patients with symptomatic HFrEF who were treated with only digoxin and diuretics.301

6.1.5.4. Cardiac glycosides Cardiac glycosides, digoxin or digitoxin, should be considered in patients with HFrEF to reduce the risk of HFH.302–304 In the DIG trial, the overall effect on mortality with digoxin was neutral but there was a reduction in HFH.303 Moreover, the effects of digoxin in patients with HFrEF and AF have not been studied in RCTs, but digoxin may be useful for the treatment of AF with rapid ventricular rate when other therapies cannot be used.305–307 A serum digoxin concentration <1.2 ng/mL should be used as a target during ongoing therapy.308 The DIGIT-HF trial examined whether low-dose digitoxin added to contemporary FMT improves outcomes in patients with chronic symptomatic HFrEF (LVEF ≤40% and NYHA class III/IV or LVEF ≤30% and NYHA class II).304 The trial included most patients in NYHA class III and, contrary to the DIG trial, also included patients with AF. They were randomized to digitoxin [starting 0.07 mg daily, then titrated to target serum concentrations (10.5–23.6 nmol/L)] vs placebo. Over a median follow-up of 36 months, the primary composite endpoint—death from any cause or HFH— occurred in 39.5% of the digitoxin group vs 44.1% of the placebo group (HR 0.82; 95% CI 0.69–0.98; P = .03). There was no significant reduction in all-cause mortality alone (27.2% vs 29.5%; HR 0.86; 95% CI 0.69–1.07) or in HFH alone (28.1% vs 30.4%;

Beta-blockers have been shown to reduce morbidity and mortality in patients with HFrEF in addition to treatment with an ACE-I and diuretics.36,287–292 Bisoprolol, sustained-release metoprolol (succinate), and carvedilol have been shown to reduce the risk of death in patients with HFrEF, whereas nebivolol only reduced the combined endpoint of all-cause mortality and CV hospitalization. An individual patient meta-analysis of RCTs of beta-blockers suggested similar reductions in CV and allcause mortality for patients in sinus rhythm with HFrEF who had LVEF <40% and LVEF 40%–50%.36 Beta-blockers should be initiated early in clinically stable patients, at low doses and gradually uptitrated to the highest tolerated dose. In patients admitted with DHF, beta-blockers should be cautiously initiated in hospital, once the patient is haemodynamically stabilized. Every effort should be made to achieve the target doses of the beta-blockers shown to be effective in major clinical trials (Table 11). Even if symptoms do not improve, long-term treatment should be maintained to reduce the risk of major CV events. The effect of beta-blockers in patients with HFrEF and AF remains uncertain. A retrospective subgroup individual-patient data meta-analysis of all major beta-blocker trials in HFrEF showed no benefit on hospital admissions and mortality in the subgroup of patients with HFrEF with AF.36,293 However, to date no RCT has ever been conducted investigating the effect of beta-blockers specifically in patients with AF and HFrEF, despite beta-blockers being potentially useful for rate control of AF.